About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma

 

HL >  ASCO 2012 - Hodgkin Lymphoma (HL)

Last update: 05/31/2012

Compiled from ASCO 2012 abstracts: Lymphoma | CLL

Comments or Questions?

 

  1. Prevention of adverse events during treatment of HIV-associated Hodgkin lymphoma with ritonavir and zidovudine. | 2012 ASCO Annual Meeting Abstracts

     
  2. Outcomes of advanced HL with ABVD: The University of Pennsylvania experience. | 2012 ASCO Annual Meeting Abstracts

     
  3. Second cancer risk 40 years after cure for Hodgkin lymphoma. | 2012 ASCO Annual Meeting Abstracts

     
  4. Early determination of treatment sensitivity in HIV-related Hodgkin lymphoma by FDG-PET/CT after two cycles of ABVD chemotherapy: A European Cooperative Study Group on AIDS and Tumors (GECAT) study. | 2012 ASCO Annual Meeting Abstracts

     
  5. Plasma viral DNA as a marker of tumor response in EBV(+) Hodgkin lymphoma in a phase III study (E2496). | 2012 ASCO Annual Meeting Abstracts

     
  6. Long-term complications after staging laparotomy for Hodgkin lymphoma. | 2012 ASCO Annual Meeting Abstracts

     
  7. ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. | 2012 ASCO Annual Meeting Abstracts

     
  8. Dual-point FDG-PET: A novel scanning technique in Hodgkin lymphoma with bulky disease. | 2012 ASCO Annual Meeting Abstracts

     
  9. Dose- and time-intensified ABVD without radiotherapy (RT) for advanced-stage Hodgkin lymphoma (HL) with mediastinal bulky disease (MBD). | 2012 ASCO Annual Meeting Abstracts

     
  10. Evaluation of MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, as a novel targeted agent with single-agent antitumor activity in mantle cell lymphoma (MCL) and Hodgkin lymphoma preclinical models. | 2012 ASCO Annual Meeting Abstracts
  11. Retreatment with brentuximab vedotin in CD30 - positive hematologic malignancies: A phase II study. | 2012 ASCO Annual Meeting Abstracts


     
  12. Stanford V chemotherapy and involved field radiotherapy for children and adolescents with unfavorable risk Hodgkin lymphoma: Results of a multi-institutional prospective clinical trial. | 2012 ASCO Annual Meeting Abstracts

     
  13. Secondary neutropenia (SN) after autologous hematopoietic stem cell transplantation (AHSCT) in patients (pts) with lymphoma. | 2012 ASCO Annual Meeting Abstracts
  14. Use of the cumulative amount of serum-free light chains (sFLC) at diagnosis and PET2 for the early identification of high risk of treatment failure in Hodgkin lymphoma (cHL). | 2012 ASCO Annual Meeting Abstracts

 
 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright 2004,  All Rights Reserved.